Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Antioxidant properties of the triaminopyridine, flupirtine.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Interferon in relapsing-remitting multiple sclerosis.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Chemotherapeutics in the treatment of multiple sclerosis.
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Extension CombiRx data show no benefit of combined MS drugs
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Gpr126 is essential for peripheral nerve development and myelination in mammals.
Genzyme provides update on U.S. LEMTRADA™ filing
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

Pages